Entelexo Biotherapeutics

Entelexo Biotherapeutics, based in Irvine, CA, is pioneering a novel class of therapeutic exosomes designed to address complex autoimmune diseases such as Rheumatoid Arthritis, Crohn's Disease, and Psoriasis. Utilizing a proprietary engineering platform, the company develops exosomes that communicate with multiple specific cell types simultaneously, aiming to provide more effective and personalized treatment options.

Since its founding in 2020, Entelexo has rapidly progressed through various developmental milestones, including the formation of a Scientific Advisory Board and completion of drug candidate development. The company's approach focuses on analyzing patient data to optimize product efficacy, representing a significant advancement in tailoring treatments that align with the intricate nature of autoimmune disorders.

Generated from the website